ASCO

COVID-19 Pushes Cancer Conference Into a Virtual Format
COVID-19 Pushes Cancer Conference Into a Virtual Format
Motley Fool
COVID-19
ASCO
ASCO 2020
pandemic
conferences
Flag link:
Did cancer clinical trials stay on track at ASCO 2019?
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
Flag link:
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs
BioCentury
FDA
ASCO
oncology
drug development
patients
clinical trials
tissue-agnostic drugs
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Flag link:
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
RAPS.org
ASCO
FDA
cancer
oncology
clinical trials
Friends of Cancer Research
Flag link:
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Forbes
ASCO
cancer
oncology
value
drug pricing
Flag link:
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
Xconomy
ASCO
oncology
IDO inhibitors
Incyte
Flag link:
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
Does a Blue Ribbon Make This Biotech Stock a Buy Now?
Motley Fool
Loxo Oncology
ASCO
LOXO-292
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study
Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study
Endpoints
Syndax Pharma
HDAC inhibitors
entinostat
Keytruda
ASCO
Flag link:
Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer
Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer
CP Wire
Inovio
ASCO
prostate cancer
clinical trials
INO-5150
Flag link:
5 takeaways from the first look at cancer's biggest conference
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Flag link:
Deal struck to mine cancer patient database for new treatment insights
Deal struck to mine cancer patient database for new treatment insights
Stat
patients
cancer
ASCO
CancerLinQ
Flag link:
ASCO spotlight presaged two more biotech IPOs angling for $215M
ASCO spotlight presaged two more biotech IPOs angling for $215M
Endpoints
ASCO
IPOs
biotech
Deciphera
DCC-2618
Nucana
Acelarin
Flag link:
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
ASCO
IDO inhibitors
CAR-T
PDL-1 inhibitors
Merck
Incyte
NewLink Genetics
Novartis
Juno Therapeutics
Bristol-Myers Squibb
Flag link:
AstraZeneca looks to DNA damage-response drugs for edge in oncology
AstraZeneca looks to DNA damage-response drugs for edge in oncology
BioPharma Dive
AstraZeneca
oncology
ASCO
Lynparza
Flag link:
Roche Still Waiting For The Big Push
Roche Still Waiting For The Big Push
Seeking Alpha
Roche
ASCO
immuno-oncology
Amgen
Merck
Bristol-Myers Squibb
Flag link:
Lilly's Alimta gets rating boost in update to ASCO's drug scorecard
Lilly's Alimta gets rating boost in update to ASCO's drug scorecard
Fierce Pharma
Eli Lilly
Alimta
ASCO
lung cancer
Flag link:
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St
biotech
ASCO
Immunogen
Exelixis
Oncothyreon
CTI BioPharma
Immunomedics
Vascular Biogenics
Flag link:
Top-Performing Biotech and Drug Stocks During ASCO '15
Top-Performing Biotech and Drug Stocks During ASCO '15
TheStreet.com
ASCO
Ignyta
Immunogen
Puma Biotechnology
AbbVie
Roche
Bristol-Myers Squibb
Seattle Genetics
Juno Therapeutics
Flag link:

Pages